Abiopharma

🔍 Tang Allan (Executive)

Company: Yext, Inc. (YEXT)

Report Date: 2026-03-20

Detailed Transactions and Holdings:

• Acquired 27,100 shares of Common Stock (Direct)
  Date: 2026-03-20 | Code: M | equity_swap_involved: 0 | shares_owned_after: 31,158.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 13,310 shares of Common Stock at $4.79 per share (Direct)
  Date: 2026-03-20 | Code: F | equity_swap_involved: 0 | shares_owned_after: 17,848.00 | transaction_form_type: 4 | Footnotes: F3
• Sold 27,100 shares of Restricted Stock Unit (Derivative)
  Date: 2026-03-20 | Code: M | equity_swap_involved: 0 | shares_owned_after: 72,900.00 | transaction_form_type: 4 | Footnotes: F1, F4, F4

Footnotes:

• F1: Each restricted stock unit represents a contingent right to receive one share of Yext, Inc.'s common stock.
• F2: Includes 4,058 shares of common stock acquired under the Yext, Inc. 2017 Employee Stock Purchase Plan on September 15, 2025.
• F3: Shares withheld to satisfy tax liability upon vesting of restricted stock units on March 20, 2026.
• F4: 27,100 of these restricted stock units vested on March 20, 2026, and 6,075 vests quarterly thereafter on each of June 20, September 20, December 20 and March 20, in each case subject to Reporting Person's continued service on each such date, until the award is fully vested on March 20, 2029.